The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

HIV Drug ResistanceHIV Drug Resistance
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Monotherapy and Resistance
Apr 29, 2001

I recently read that: "Upon initiation of either nevirapine and lamivudine as monotherapy, high-level resistance emerges within days to weeks" This sounds so completely amazing. Does this mean that lots of people in Asia who are on monotherapy could conceivably be spreading around very resistant virus??

Response from Dr. Little

Monotherapy with lamivudine and nevirapine do typically result in the development of drug resistance within a period of weeks. For this reason, these drugs should be used with other potent drugs. It is also true however, that some therapy is probably better than no therapy. The issues relating to use of therapy in the developing world are very controversial and no one in the field has an easy answer. I will tell you that there are two sides to the discussion: 1. It is unethical to deny therapy to any infected individual and 2. Therapy that does not result in complete control of virus is likely to be associated with more frequent transmission of drug resistant variants.

Use of only one resistance test
Medicaid and resistence testing

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint